Postgrad Med J

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bott, S R J
Right arrow Articles by Kirby, R S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bott, S R J
Right arrow Articles by Kirby, R S
Postgraduate Medical Journal 2003;79:575-580
© 2003 Fellowship of Postgraduate Medicine


BEST PRACTICE

Prostate cancer management: (1) an update on localised disease

S R J Bott 1, A J Birtle 1, C J Taylor 1, R S Kirby 2

1 Institute of Urology, London
2 St George’s Hospital, London

Correspondence to:
Correspondence to:
Mr Simon R J Bott
Prostate Cancer Research Centre, Charles Bell House, 67 Riding House Street, London W1W 7EY, UK; simonrjbott{at}hotmail.com


ABSTRACT
Prostate cancer is receiving ever more publicity with the result that more men are having their prostate specific antigen checked and a greater proportion of men are diagnosed with potentially curable localised disease. Advances in the therapeutic modalities including radical surgery, external beam radiotherapy, and brachytherapy have reduced the incidence of side effects and now offer patients a choice of treatments depending on their tumour characteristics, age, and co-morbidity. A significant proportion of men do not need intervention and may be safely kept under a "watch and wait" policy. The use of genetic markers may in the future distinguish between patients most likely to benefit from radical therapy and those in who either palliation or observation is more appropriate. This review examines the potentially curative options, as well as expectant management, outlining the pros and cons of each. The use of adjuvant and neoadjuvant therapy is also discussed.


Keywords: prostate cancer; radical prostatectomy; external beam radiotherapy; brachytherapy; androgen ablation

Abbreviations: CI, confidence interval; EBRT, external beam radiotherapy; PSA, prostate specific antigen; TNM, tumour, nodes, and metastasis; UICC, Union Internationale Contre Cancer




This article has been cited by other articles:


Home page
Postgrad. Med. J.Home page
S R J Bott, A J Birtle, C J Taylor, and R S Kirby
Prostate cancer management: (2) an update on locally advanced and metastatic disease
Postgrad. Med. J., November 1, 2003; 79(937): 643 - 645.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2003 The Fellowship of Postgraduate Medicine